Sanofi Faces Ongoing Supply Shortage of Pompe Disease Treatments Due to Manufacturing Issues

Sanofi (SNY) is experiencing a prolonged shortage of its Pompe disease treatments, Lumizyme and Nexviazyme, which has lasted for over three months. The company attributed the disruption to manufacturing issues at its facility in Ireland. While Sanofi claims progress is being made in some regions, shipping delays may continue to affect U.S. patients through the end of November. The shortage stems from FDA-identified violations at the Irish plant. Despite responding to initial inspections in early 2026, a subsequent FDA warning letter in June indicated that Sanofi had failed to address underlying manufacturing compliance failures. This has caused significant distress among the rare disease community, as interruptions in these bi-weekly enzyme replacement therapies can lead to irreversible muscle weakness and health decline.

By Gerry Smith,Brad Quick · CNBC ·

Sanofi Faces Ongoing Supply Shortage of Pompe Disease Treatments Due to Manufacturing Issues

Tickers: $SNY

Topics: drug shortage manufacturing issues Pompe disease supply chain disruption

Read the full article at CNBC

More World news